Clinical Trials (recruiting subjects)

AML-18
A trial for older patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome

AML-LI1
A programme of development for older patients with acute myeloid leukaemia and high-risk myelodysplastic syndrome

ARROW/CFZ014
A randomized, open-label, phase III study in subjects with relapsed and refractory multiple myeloma receiving carfilzomib in combination with dexamethasone, comparing once-weekly versus twice-weekly carfilzomib dosing

C16019
A Phase 3, randomized, placebo-controlled, double-blind study of oral ixazomib citrate (MLN9708) maintenance therapy in patients with multiple myeloma following autologous stem cell transplant

CARFI
Phase II study of carfilzomib-cyclophosphamide-dexamethasone and high-dose melphalan followed by randomization between observation or maintenance with carfilzomib and dexamethasone in patients with relapsed multiple myeloma after high-dose melphalan with autologous stem cell support

CLAIM
A randomized placebo-controlled phase II study of clarithromycin or placebo combined with VCD induction therapy prior to high-dose melphalan with stem cell support in patients with newly diagnosed multiple myeloma

CLL-14
A prospective, open-label, multicenter randomized phase III trial to compare the efficacy and safety of a combined regimen of obinutuzumab and venetoclax (gdc-0199/abt-199) versus obinutuzumab and chlorambucil in previously untreated patients with CLL and coexisting medical conditions

GS-US-312-0133
A phase II, single arm study evaluating the efficacy and safety of idelalisib in combination with rituximab in patients with previously untreated chronic lymphocytic leukemia with 17p deletion

HOVON126
Ixazomib citrate-thalidomide-low dose dexamethasone induction followed by maintenance therapy with ixazomib citrate or placebo in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplantation; a randomized phase II trial

Kaleidoscope CC-5013-MDS-010
A prospective non-interventional postauthorization safety study (PASS), designed as a disease registry of patients with transfusion dependent IPSS low or intermediate-1-risk myelodysplastic syndromes (MDS) and isolated del(5q)

MEXO
An observational study in patients with newly diagnosed multiple myeloma (IgA or IgG) aged between 60 and 70.

MDS Nordic Biobank
Fra *in vitro* til *in vivo* monitorering af betydningen af DNA- og histonmetylering ved hæmatologiske maligniteter: *Fokus på behandling rettet mod epigenetiske forandringer*

PHASE 0 R-CHOP
Preclinical phase 0 micro dose study to evaluate the effect of R-CHOP chemotherapy on cellular gene-expression. Establisment of a preclinical model for in vivo evaluation of molecular biological effects.

PIX306
A phase III study of pixantrone. A randomized multicenter study comparing pixantrone + rituximab with gemcitabine + rituximab in patients with aggressive B-cell non-Hodgkin lymphoma who have relapsed after therapy with CHOP-R or an equivalent regimen and are ineligible for stem cell transplant

PROGENE
Ny klassifikation af maligne blodsygdomme - Implementering via et tofaset prospektivt registrerings- og valideringsstudie ved relaps

SUTRICA
A randomized, open-label phase III study of clarithromycin, sulfamethoxazole/trimethoprim or observation in combination with standard therapy in patients with newly diagnosed multiple myeloma

August 2016/Lise Tordrup Elkjær